Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804082 | 0.82 | ALDH1A1 (0.41) | L3MBTL1POLBNPC1SMN1; SMN2MAPT | |
| SCHEMBL10039636 | 0.82 | ALDH1A1 (0.41) | L3MBTL1POLBLMNANPC1SMN1; SMN2 | |
| SCHEMBL6974124 | 0.81 | L3MBTL1 (0.56) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL1970601 | 0.81 | L3MBTL1 (0.56) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL3663807 | 0.80 | ALDH1A1 (0.63) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL20117157 | 0.79 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL7277285 | 0.79 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL2906606 | 0.79 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL4259604 | 0.79 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL5606459 | 0.79 | ALDH1A1 (0.62) | L3MBTL1POLBLMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2125038-B1 | RADIOACTIVE PET AGENTS FOR IMAGING CCR5 IN VIVO | GE HEALTHCARE LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| WO-2008075040-A2 | IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129419-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | L3MBTL1 1414/4885POLB 4056/4885LMNA 2853/4885 |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | L3MBTL1 1414/4885POLB 4056/4885LMNA 2853/4885 |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | L3MBTL1 1414/4885POLB 4056/4885LMNA 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.